EVENT 20-22 MARCH 2018
Prof. F. Wurm will provide a keynote lecture: CHO: Optimizing Cell Culture Technologies for Manufacturing of Recombinant Proteins – Past, Presence and Future at the Bioprocessing Summit Europe conference in Lisbon on March 20th.
Dr. Maria Wurm, CEO of ExcellGene will provide a seminar on Bioreactor-Based Optimization and Scale-up Issues for Large Scale Manufacture with Suspension Cultures of Animal Cells, on March 22.
In an article written in November 2017 by Dr. Angelo DePalma in Genetic Engineering and Biotechnology News (GEN), ExcellGene and Prof. F. Wurm were referred to discussing the benefits of better media and feeds as the main driver for the higher yields from CHO cells and the processes developed for large scale manufacturing. This conclusion is based on more than 3 decades of observation and analysis of CHO cells for manufacturing purposes…
WHAT WE DO
Everything from DNA vector to purified product and process for large-scale manufacturing.
We cover the value chain from DNA construction & transfection, to scalable process development, to rapid protein manufacture or VLP production and the development of scalable (GMP) processes.
ExcellGene™ technologies are the most advanced for rapid production of recombinant proteins or virus vectors – transient or stable.
From DNA to high-yielding clonal population.
Rapid Protein Production
Production in weeks from 1mL to 100L scale.
Process Development for High Yield
Fine-tuning of media and process conditions, parameters for virus or protein.
HEK cell-based production 1ml to 10L; no baculo virus use.
cGMP Master Cell Banking
Compliant with GMP standards.
Science-driven, on every level.
The company has developed proprietary technologies and know-how that are key for the delivery of its clients’ projects on a timely manner and with a high degree of customization.
Some are also available to license.
Clients from all around the world.
ExcellGene has assisted more than a hundred clients since inception, which include 6 of the top 10 pharma companies, biotech companies, contract research organizations and academic institutions.
- Biotech 47%
- Big pharma 25%
- Academic 10%
- Other 18%